Intracellular fate of peptide-mediated delivered cargoes

Current Pharmaceutical Design

Volumn 19, Issue 16, 2013, Pages 2924-2942

  Martín, Irene ^a   Teixidó, Meritxell ^a   Giralt, Ernest ^a,b  

^a INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Cell penetrating peptides; Drug delivery; Internalization mechanism; Quantum dot delivery and nucleic acid delivery

Indexed keywords

BAFILOMYCIN A1; BREFELDIN A; CARBOXYFLUORESCEIN; CELL PENETRATING PEPTIDE; CHLORPROMAZINE; CRE RECOMBINASE; CYTOCHALASIN D; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUORESCEIN ISOTHIOCYANATE; NITRIC OXIDE SYNTHASE; PENETRATIN; PHOSPHATIDYLINOSITOL 3 KINASE; QUANTUM DOT; RHODAMINE; WORTMANNIN;

AMINO ACID SEQUENCE; BRAIN ISCHEMIA; CAVEOLA; CELLULAR DISTRIBUTION; CHANNEL GATING; CHEMICAL MODIFICATION; CONFORMATIONAL TRANSITION; DRUG DELIVERY SYSTEM; ENDOCYTOSIS; ENDOPLASMIC RETICULUM; ENDOSOME; EXTRACELLULAR MATRIX; GAMMA COUNTER; GOLGI COMPLEX; HUMAN; HYDROPHILICITY; HYDROPHOBICITY; INCUBATION TIME; INTERNALIZATION; IODINATION; LIPID BILAYER; LIPID RAFT; MEMBRANE FLUIDITY; MEMBRANE POTENTIAL; MICROTUBULE ORGANIZING CENTER; NUCLEAR LOCALIZATION SIGNAL; PHAGOCYTOSIS; PHASE 2 CLINICAL TRIAL (TOPIC); PINOCYTOSIS; POLYMERIZATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN SECONDARY STRUCTURE; QUANTITATIVE ANALYSIS; REVIEW; RNA TRANSLATION;

ANIMALS; CELL-PENETRATING PEPTIDES; DRUG DELIVERY SYSTEMS; GENE TRANSFER TECHNIQUES; HUMANS; NUCLEIC ACIDS; QUANTUM DOTS;

EID: 84878623235     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811319160007     Document Type: Review

References (306)

1. Asimov I. Fantastic voyage: Bantam Books; 1966.
2. Udhrain A, Skubitz KM, Northfelt DW. Pegylated liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma Int J Nanomedicine 2007; 2: 345-52.
3. James ND, Coker RJ, Tomlinson D, et al. Liposomal doxorubicin (Doxil): An effective new treatment for Kaposi's sarcoma in AIDS. J Clin Oncol 1994; 6: 294-6.
4. Gitton Y, Tibaldi L, Dupont E, Levi G, Joliot A. Efficient CPPmediated Cre protein delivery to developing and adult CNS tissues. BMC Biotechnology 2009; 9: 40.
5. Stewart KM, Horton KL, Kelley SO. Cell-penetrating peptides as delivery vehicles for biology and medicine. Org Biomol Chem 2008; 6: 2242-55.
6. Torchilin VP. Tat peptide-mediated intracellular delivery of pharmaceutical nanocarriers. Adv Drug Deliv Rev 2008; 60: 548-58.
7. Meade BR, Dowdy SF. Exogenous siRNA delivery using peptide transduction domains/cell penetrating peptides. Adv Drug Deliv Rev 2007; 59: 134-40.
8. Pujals S, Bastús NG, Pereiro E, et al. Shuttling gold nanoparticles into tumoral cells with an amphipathic proline-rich peptide. ChemBioChem 2009; 10: 1025-31.
9. Liu BR, Huang Y-w, Winiarz JG, Chiang H-J, Lee H-J. Intracellular delivery of quantum dots mediated by a histidine-and arginine-rich HR9 cell-penetrating peptide through the direct membrane translocation mechanism. Biomaterials 2011; 32: 3520-37.
10. Frankel AD, Pabo CO. Cellular uptake of the tat protein from human immunodeficiency virus. Cell 1988; 55: 1189-93.
11. Derossi D, Calvet S, Trembleau A, Brunissen A, Chassaing G, Prochiantz A. Cell internalization of the third helix of the Antennapedia homeodomain is receptor-independent. J Biol Chem 1996; 271: 18188-93.
12. Vivès E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J Biol Chem 1997; 272: 16010-7.
13. Futaki S, Suzuki T, Ohashi W, et al. Arginine-rich peptides. J Biol Chem 2001; 276: 5836-40.
14. Oehlke J, Scheller A, Wiesner B, et al. Cellular uptake of an alphahelical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim Biophys Acta 1998; 1414: 127-39.
15. Morris MC, Vidal P, Chaloin L, Heitz F, Divita G. A new peptide vector for efficient delivery of oligonucleotides into mammalian cells. Nucleic Acids Res 1997; 25: 2730-6.
16. Crombez L, Aldrian-Herrada G, Konate K, et al. A new potent secondary amphipathic cell-penetrating peptide for siRNA delivery into mammalian cells. Mol Ther 2008; 17: 95-103.
17. Pooga M, Hällbrink M, Zorko M, Langel Ü. Cell penetration by transportan. FASEB J 1998; 12: 67-77.
18. Soomets U, Lindgren M, Gallet X, et al. Deletion analogues of transportan. Biochim Biophys Acta 2000; 1467: 165-76.
19. Arrighi RBG, Ebikeme C, Jiang Y, et al. Cell-penetrating peptide TP10 shows broad-spectrum activity against both Plasmodium falciparum and Trypanosoma brucei brucei. Antimicrob Agents Chemother 2008; 52: 3414-7.
20. Martín I, Teixidó M, Giralt E. Design, synthesis and characterization of a new anionic cell-penetrating peptide: SAP(E) ChemBioChem 2011; 12: 896-903.
21. Foged C, Nielsen HM. Cell-penetrating peptides for drug delivery across membrane barriers. Expert Opin Drug Deliv 2008; 5: 105-17.
22. Heitz F, Morris MC, Divita G. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br J Pharmacol 2009; 157: 195-206.
23. Mathupala SP. Delivery of small-interfering RNA (siRNA) to the brain. Expert Opin Ther Pat 2009; 19: 137-40.
24. Kamei N, Morishita M, Eda Y, Ida N, Nishio R, Takayama K. Usefulness of cell-penetrating peptides to improve intestinal insulin absorption. J Control Release 2008; 132: 21-5.
25. Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer. Biochim Biophys Acta 2011; 1816: 232-46.
26. Snyder EL, Dowdy SF. Cell penetrating peptides in drug delivery. Pharm Res 2004; 21: 389-93.
27. Vivès E, Schmidt J, Pèlegrin A. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim Biophys Acta 2008; 1786: 126-38.
28. Richard JP, Melikov K, Vivès E, et al. Cell-penetrating Peptides. J Biol Chem 2003; 278: 585-90.
29. Schmidt N, Mishra A, Lai GH, Wong GCL. Arginine-rich cellpenetrating peptides. FEBS Lett 2010; 584: 1806-13.
30. Järver P, Langel Ü. Cell-penetrating peptides-A brief introduction. Biochim Biophys Acta 2006; 1758: 260-3.
31. Morris MC, Deshayes S, Heitz F, Divita G. Cell-penetrating peptides: From molecular mechanisms to therapeutics. Biol Cell 2008; 100: 201-17.
32. Suhorutsenko J, Oskolkov N, Arukuusk P, et al. Cell-penetrating peptides, PepFects, show no evidence of toxicity and immunogenicity in vitro and in vivo. Bioconjug Chem 2011; 22: 2255-62.
33. Joliot A, Pernelle C, Deagostini-Bazin H, Prochiantz A. Antennapedia homeobox peptide regulates neural morphogenesis. Proc Natl Acad Sci USA 1991; 88: 1864-8.
34. Elmquist A, Lindgren M, Bartfai T, Langel Ü. VE-Cadherinderived cell-penetrating peptide, pVEC, with carrier functions. Exp Cell Res 2001; 269: 237-44.
35. El-Andaloussi S, Johansson HJ, Holm T, Langel Ü. A novel cellpenetrating peptide, M918, for efficient delivery of proteins and peptide nucleic acids. Mol Ther 2007; 15: 1820-6.
36. Fernández-Carneado J, Kogan MJ, Castel S, Giralt E. Potential peptide carriers: amphipathic proline-rich peptides derived from the N-terminal domain of gamma-zein. Angew Chem Int Ed Engl 2004; 43: 1811-4.
37. Elliott G, O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997; 88: 223-33.
38. Morris MC, Depollier J, Mery J, Heitz F, Divita G. A peptide carrier for the delivery of biologically active proteins into mammalian cells. Nat Biotechnol 2001; 19: 1173-6.
39. Abes R, Moulton HM, Clair P, et al. Delivery of steric block morpholino oligomers by (R-X-R)4 peptides: structure-activity studies. Nucleic Acids Res 2008: 6343-54.
40. Eiríksdóttir E, Konate K, Langel Ü, Divita G, Deshayes S. Secondary structure of cell-penetrating peptides controls membrane interaction and insertion. Biochim Biophys Acta 2010; 1798: 1119-28.
41. Melikov K, Chernomordik L. Arginine-rich cell penetrating peptides: from endosomal uptake to nuclear delivery. Cell Mol Life Sci 2005; 62: 2739-49.
42. Vivès E, Brodin P, Lebleu B. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. Journal of Biological Chemistry 1997; 272: 16010-7.
43. Pujals S, Fernández-Carneado J, Ludevid MD, Giralt E. D-SAP: A new, noncytotoxic, and fully protease resistant cell-penetrating peptide. ChemMedChem 2008; 3: 296-301.
44. Krauss U, Müller M, Stahl M, Beck-Sickinger AG. In vitro gene delivery by a novel human calcitonin (hCT)-derived carrier peptide. Bioorg Med Chem Lett 2004; 14: 51-4.
45. Schmidt MC, Rothen-Rutishauser B, Rist B, et al. Translocation of human calcitonin in respiratory nasal epithelium is associated with self-assembly in lipid membrane. Biochemistry 1998; 37: 16582-90.
46. Rodrigues M, de la Torre BG, Rádis-Baptista G, Santos NC, Andreu D. Efficient cellular delivery of β-Galactosidase mediated by NrTPs, a new family of cell-penetrating peptides. Bioconjug Chem 2011; 22: 2339-44.
47. Rádis-Baptista G, de la Torre BG, Andreu D. A novel cellpenetrating peptide sequence derived by structural minimization of a snake toxin exhibits preferential nucleolar localization. J Med Chem 2008; 51: 7041-4.
48. Lebleu B, Moulton HM, Abes R, et al. Cell penetrating peptide conjugates of steric block oligonucleotides. Adv Drug Deliv Rev 2008; 60: 517-29.
49. Endoh T, Ohtsuki T. Cellular siRNA delivery using cellpenetrating peptides modified for endosomal escape. Adv Drug Deliv Rev 2009; 61: 704-9.
50. Mishra R, Su W, Pohmann R, et al. Cell-penetrating peptides and peptide nucleic acid-coupled MRI contrast agents: evaluation of cellular delivery and target binding. Bioconjug Chem 2009; 20: 1860-8.
51. Rapoport M, Lorberboum-Galski H. TAT-based drug delivery system-new directions in protein delivery for new hopes? Expert Opin Drug Deliv 2009; 6: 453-63.
52. Fonseca SB, Pereira MP, Kelley SO. Recent advances in the use of cell-penetrating peptides for medical and biological applications. Adv Drug Deliv Rev 2009; 61: 953-64.
53. Liu BR, Huang Y-W, Chiang H-J, Lee H-J. Cell-penetrating peptide-functionalized quantum dots for intracellular delivery. J Nanosci Nanotechnol 2010; 10: 7897-905.
54. Marin S, Pujals S, Giralt E, Merkoçi A. Electrochemical investigation of cellular uptake of quantum dots decorated with a proline-rich cell penetrating peptide. Bioconjug Chem 2011; 22: 180-5.
55. Liu BR, Li JF, Lu SW, et al. Cellular internalization of quantum dots noncovalently conjugated with arginine-rich cell-penetrating peptides. J Nanosci Nanotechnol 2010; 10: 6534-43.
56. Medintz IL, Pons T, Delehanty JB, et al. Intracellular delivery of quantum dot-protein cargos mediated by cell penetrating peptides. Bioconjug Chem 2008; 19: 1785-95.
57. Lewin M, Carlesso N, Tung C-H, Tang X-W, Cory D, Scadden DT, et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat Biotechnol 2000; 18: 410-4.
58. Fawell S, Seery J, Daikh Y, et al. Tat-mediated delivery of heterologous proteins into cells. Proc Natl Acad Sci USA 1994; 91: 664-8.
59. Justesen S, Buus S, Claesson MH, Pedersen AE. Addition of TAT protein transduction domain and GrpE to human p53 provides soluble fusion proteins that can be transduced into dendritic cells and elicit p53-specific T-cell responses in HLA-A*0201 transgenic mice. Immunology 2007; 122: 326-34.
60. Wadia JS, Dowdy SF. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev 2005; 57: 579-96.
61. Harada H, Kizaka-Kondoh S, Hiraoka M. Antitumor protein therapy; Application of the protein transduction domain to the development of a protein drug for cancer treatment. Breast Cancer 2006; 13: 16-26.
62. Zhou Y, Du W, Koretsky T, Bagby GC, Pang Q. TAT-mediated intracellular delivery of NPM-derived peptide induces apoptosis in leukemic cells and suppresses leukemogenesis in mice. Blood 2008; 112: 2474-83.
63. Kubo E, Fatma N, Akagi Y, Beier DR, Singh SP, Singh DP. TATmediated PRDX6 protein transduction protects against eye lens epithelial cell death and delays lens opacity. Am J Physiol Cell Physiol 2008; 294: 842-55.
64. Wang Q, Gou X, Jin W, et al. TAT-mediated protein transduction of Nogo extracellular peptide 1-40 and its biological activity. Cell Mol Neurobiol 2009; 29: 97-108.
65. Kim DW, Kim CK, Choi SH, et al. Tat-mediated protein transduction of human brain pyridoxal kinase into PC12 cells. Biochimie 2005; 87: 481-7.
66. Toro A, Grunebaum E. TAT-mediated intracellular delivery of purine nucleoside phosphorylase corrects its deficiency in mice. J Clin Invest 2006; 116: 2717-26.
67. Rapoport M, Saada A, Elpeleg O, Lorberboum-Galski H. TATmediated delivery of LAD restores pyruvate dehydrogenase complex activity in the mitochondria of patients with LAD deficiency. Mol Ther 2008; 16: 691-7.
68. Eavri R, Lorberboum-Galski H. A novel approach for enzyme replacement therapy. J Biol Chem 2007; 282: 23402-9.
69. Rudolph C, Schillinger U, Ortiz A, et al. Application of novel solid lipid nanoparticle (SLN)-gene vector formulations based on a dimeric HIV-1 TAT-peptide in vitro and in vivo. Pharm Res 2004; 21: 1662-9.
70. Liu L, Guo K, Lu J, et al. Biologically active core/shell nanoparticles self-assembled from cholesterol-terminated PEGTAT for drug delivery across the blood-brain barrier. Biomaterials 2008; 29: 1509-17.
71. Liu L, Venkatraman SS, Yang YY, et al. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood-brain barrier. Pept Sci 2008; 90: 617-23.
72. Rao KS, Reddy MK, Horning JL, Labhasetwar V. TAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugs. Biomaterials 2008; 29: 4429-38.
73. Kale AA, Torchilin VP. Enhanced transfection of tumor cells in vivo using "Smart" pH-sensitive TAT-modified pegylated liposomes. J Drug Target 2007; 15: 538-45.
74. Torchilin VP. Cell penetrating peptide-modified pharmaceutical nanocarriers for intracellular drug and gene delivery. Pept Sci 2008; 90: 604-10.
75. Torchilin VP, Levchenko TS. TAT-liposomes: a novel intracellular drug carrier. Curr Protein Pept Sci 2003; 4: 133-40.
76. Tseng YL, Liu JJ, Hong RL. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and Tat: A kinetic and efficacy study. Mol Pharmacol 2002; 62: 864-72.
77. Torchilin VP, Rammohan R, Weissig V, Levchenko TS. TAT peptide on the surface of liposomes affords their efficient intracellular delivery even at low temperature and in the presence of metabolic inhibitors. Proc Natl Acad Sci USA 2001; 98: 8786-91.
78. Fretz MM, Koning GA, Mastrobattista E, Jiskoot W, Storm G. OVCAR-3 cells internalize TAT-peptide modified liposomes by endocytosis. Biochim Biophys Acta 2004; 1665: 48-56.
79. Marty C, Meylan C, Schott H, Ballmer-Hofer K, Schwendener RA. Enhanced heparan sulfate proteoglycan-mediated uptake of cellpenetrating peptide-modified liposomes. Cell Mol Life Sci 2004; 61: 1785-94.
80. Qin Y, Chen H, Zhang Q, et al. Liposome formulated with TATmodified cholesterol for improving brain delivery and therapeutic efficacy on brain glioma in animals. Int J Pharm 2011; 420: 304-12.
81. Niu R, Zhao P, Wang H, et al. Preparation, characterization, and antitumor activity of paclitaxel-loaded folic acid modified and TAT peptide conjugated PEGylated polymeric liposomes. J Drug Target 2011; 19: 373-81.
82. Zhao P, Wang H, Yu M, et al. Paclitaxel-loaded, folic-acid-targeted and TAT-peptide-conjugated polymeric liposomes: In vitro and in vivo evaluation. Pharm Res 2010; 27: 1914-26.
83. de la Fuente JM, Berry CC. Tat peptide as an efficient molecule to translocate gold nanoparticles into the cell nucleus. Bioconjug Chem 2005; 16: 1176-80.
84. Berry CC. Nuclear localization of HIV-1 tat functionalized gold nanoparticles. IEEE Trans Nanobioscience 2007; 4: 262-9.
85. Bhorade R, Weissleder R, Nakakoshi T, Moore A, Tung CH. Macrocyclic chelators with paramagnetic cations are internalized into mammalian cells via a HIV-Tat derived membrane translocation peptide. Bioconjug Chem 2000; 11: 301-5.
86. Sethuraman VA, Bae YH. TAT peptide-based micelle system for potential active targeting of anti-cancer agents to acidic solid tumors. J Control Release 2007; 118: 216-24.
87. Sawant RR, Torchilin VP. Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm 2009; 374: 114-8.
88. Lee ES, Gao Z, Kim D, Park K, Kwon IC, Bae YH. Super pHsensitive multifunctional polymeric micelle for tumor pHe specific TAT exposure and multidrug resistance. J Control Release 2008; 129: 228-36.
89. Xue F, Chen J, Guo J, et al. Enhancement of intracellular delivery of CdTe quantum dots (QDs) to living cells by Tat conjugation. J Fluoresc 2007; 17: 149-54.
90. de la Fuente JM, Fandel M, Berry CC, et al. Quantum dots protected with tiopronin: a new fluorescence system for cellbiology studies. ChemBioChem 2005; 6: 989-91.
91. Nitin N, LaConte L, Rhee W, Bao G. Tat peptide is capable of importing large nanoparticles across nuclear membrane in digitonin permeabilized cells. Ann Biomed Eng 2009; 37: 2018-27.
92. Lei Y, Tang H, Yao L, Yu R, Feng M, Zou B. Applications of mesenchymal stem cells labeled with Tat peptide conjugated quantum dots to cell tracking in mouse body. Bioconjug Chem 2007; 19: 421-7.
93. Chen B, Liu Q, Zhang Y, Xu L, Fang X. Transmembrane delivery of the cell-penetrating peptide conjugated semiconductor quantum dots. Langmuir 2008; 24: 11866-71.
94. Koshman YE, Waters SB, Walker LA, Los T, Tombe Pd, Goldspink PH, et al. Delivery and visualization of proteins conjugated to quantum dots in cardiac myocytes. J Mol Cell Cardiol 2008; 45: 853-6.
95. Santra S, Yang H, Stanley JT, et al. Rapid and effective labeling of brain tissue using TAT-conjugated CdSMn/ZnS quantum dots. Chem Commun 2005: 3144-6.
96. Ruan G, Agrawal A, Marcus AI, Nie S. Imaging and tracking of tat peptide-conjugated quantum dots in living cells: new insights into nanoparticle uptake, intracellular transport, and vesicle shedding. J Am Chem Soc 2007; 129: 14759-66.
97. Kim K, Han J, Kim H, Lee M. Expression, purification and characterization of TAT-high mobility group box-1A peptide as a carrier of nucleic acids. Biotechnol Lett 2008; 30: 1331-7.
98. Meade BR, Dowdy SF. Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliv Rev 2008; 60: 530-6.
99. Moschos SA, Jones SW, Perry MM, et al. Lung selivery studies using siRNA conjugated to TAT(48-60) and Penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjugate Chemistry 2007; 18: 1450-9.
100. Chiu Y-L, Ali A, Chu C-y, Cao H, Rana TM. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 2004; 11: 1165-75.
101. Turner JJ, Jones S, Fabani MM, Ivanova G, Arzumanov AA, Gait MJ. RNA targeting with peptide conjugates of oligonucleotides, siRNA and PNA. Blood Cells, Molecules, and Diseases 2006; 38: 1-7.
102. Xavier J, Singh S, Dean DA, Rao NM, Gopal V. Designed multidomain protein as a carrier of nucleic acids into cells. J Control Release 2009; 133: 154-60.
103. Bolhassani A, Ghasemi N, Servis C, Taghikhani M, Rafati S. The efficiency of a novel delivery system (PEI600-Tat) in development of potent DNA vaccine using HPV16 E7 as a model antigen. Drug Deliv 2009; 16: 196-204.
104. Folini M, Bandiera R, Millo E, et al. Photochemically enhanced delivery of a cell-penetrating peptide nucleic acid conjugate targeting human telomerase reverse transcriptase: effects on telomere status and proliferative potential of human prostate cancer cells. Cell Prolif 2007; 40: 905-20.
105. Bendifallah N, Rasmussen FW, Zachar V, Ebbesen P, Nielsen PE, Koppelhus U. Evaluation of cell-penetrating peptides (CPPs) as vehicles for intracellular delivery of antisense peptide nucleic acid (PNA). Bioconjug Chem 2006; 17: 750-8.
106. Moschos SA, Williams AE, Lindsay MA. Cell-penetrating-peptidemediated siRNA lung delivery. Biochem Soc Trans 2007; 35: 807-10.
107. Baoum A, Xie S-X, Fakhari A, Berkland C. "Soft" calcium crosslinks enable highly efficient gene transfection using TAT peptide. Pharm Res 2009; 26: 2619-29.
108. Ignatovich IA, Dizhe EB, Pavlotskaya AV, et al. Complexes of plasmid DNA with basic domain (47-57) of the HIV-1 Tat protein are transferred to mammalian cells by endocytosis-mediated pathways. J Biol Chem 2003; 278: 42625-36.
109. Moulton H, Moulton J. Antisense morpholino oligomers and theirs peptide conjugates. In: J K, editor. Therapeutic Oligonucleotide. Cambridge: Royal Society of Chemistry; 2008. p. 43-79.
110. Hällbrink M, Florén A, Elmquist A, Pooga M, Bartfai T, Langel Ü. Cargo delivery kinetics of cell-penetrating peptides. Biochim Biophys Acta 2001; 1515: 101-9.
111. Corradin S, Ransijn A, Corradin G, et al. Novel peptide inhibitors of Leishmania gp63 based on the cleavage site of MARCKS (myristoylated alanine-rich C kinase substrate)-related protein. Biochem J 2002; 367: 761-9.
112. Datta K, Sundberg C, Karumanchi SA, Mukhopadhyay D. The 104-123 amino acid sequence of the beta-domain of von Hippel-Lindau gene product is sufficient to inhibit renal tumor growth and invasion. Cancer Res 2001; 61: 1768-75.
113. Pouniotis DS, Esparon S, Apostolopoulos V, Pietersz GA. Whole protein and defined CD8+ and CD4+ peptides linked to penetratin targets both MHC class I and II antigen presentation pathways. Immunol Cell Biol 2011; 89: 904-13.
114. Schutze-Redelmeier MP, Gournier H, Garcia-Pons F, et al. Introduction of exogenous antigens into the MHC class I processing and presentation pathway by Drosophila antennapedia homeodomain primes cytotoxic T cells in vivo. J Immunol 1996; 157: 650-5.
115. Eiríksdóttir E, Mäger I, Lehto T, El Andaloussi S, Langel Ü. Cellular internalization kinetics of (luciferin-)cell-penetrating peptide conjugates. Bioconjug Chem 2010; 21: 1662-72.
116. Banoczi Z, Tantos A, Farkas A, Tompa P, Friedrich P, Hudecz F. Synthesis of cell-penetrating conjugates of calpain activator peptides. Bioconjug Chem 2006; 18: 130-7.
117. Pouniotis DS, Apostolopoulos V, Pietersz GA. Penetratin tandemly linked to a CTL peptide induces anti-tumour T-cell responses via a cross-presentation pathway. Immunology 2006; 117: 329-39.
118. Kersemans V, Kersemans K, Cornelissen B. Cell penetrating peptides for in vivo molecular imaging applications. Curr Pharm Des 2008; 14: 2415-27.
119. Muratovska A, Eccles MR. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 2004; 558: 63-8.
120. Davidson TJ, Harel S, Arboleda VA, et al. Highly efficient small interfering RNA delivery to primary mammalian neurons induces MicroRNA-like effects before mRNA degradation. J Neurosci 2004; 24: 10040-6.
121. Schratt GM, Tuebing F, Nigh EA, et al. A brain-specific microRNA regulates dendritic spine development. Nature 2006; 439: 283-9.
122. Mäe M, El Andaloussi S, Lundin P, et al. A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J Control Release 2009; 134: 221-7.
123. Pooga M, Soomets U, Hallbrink M, et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat Biotechnol 1998; 16: 857-61.
124. 2-terminal kinase. Biochem Biophys Res Commun 2010; 396: 908-14.
125. Aroui S, Brahim S, Waard MD, Kenani A. Cytotoxicity, intracellular distribution and uptake of doxorubicin and doxorubicin coupled to cell-penetrating peptides in different cell lines: A comparative study. Biochem Biophys Res Commun 2010; 391: 419-25.
126. Wang S, Zhelev NZ, Duff S, Fischer PM. Synthesis and biological activity of conjugates between paclitaxel and the cell delivery vector penetratin. Bioorg Med Chem Lett 2006; 16: 2628-31.
127. Barnes MP, Shen W-C. Disulfide and thioether linked cytochrome c-oligoarginine conjugates in HeLa cells. Int J Pharm 2009; 369: 79-84.
128. Takayama K, Nakase I, Michiue H, et al. Enhanced intracellular delivery using arginine-rich peptides by the addition of penetration accelerating sequences (Pas) J Control Release 2009; 138: 128-33.
129. Futaki S, Niwa M, Nakase I, et al. Arginine carrier peptide bearing Ni(II) chelator to promote cellular uptake of histidine-tagged proteins. Bioconjug Chem 2004; 15: 475-81.
130. Maitani Y, Hattori Y. Oligoarginine-PEG-lipid particles for gene delivery. Expert Opin Drug Deliv 2009; 6: 1065-77.
131. Shishido T, Yonezawa D, Iwata K, et al. Construction of argininerich peptide displaying bionanocapsules. Bioorg Med Chem Lett 2009; 19: 1473-6.
132. Wu RP, Youngblood DS, Hassinger JN, et al. Cell-penetrating peptides as transporters for morpholino oligomers: effects of amino acid composition on intracellular delivery and cytotoxicity. Nucleic Acids Res 2007; 35: 5182-91.
133. Kim WJ, Christensen LV, Jo S, et al. Cholesteryl oligoarginine delivering vascular endothelial growth factor siRNA effectively inhibits tumor growth in colon adenocarcinoma. Mol Ther 2006; 14: 343-50.
134. Kumar P, Wu H, McBride JL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature 2007; 448: 39-43.
135. Takayama K, Tadokoro A, Pujals S, Nakase I, Giralt E, Futaki S. Novel system to achieve one-pot modification of cargo molecules with oligoarginine vectors for intracellular delivery. Bioconjug Chem 2009; 20: 249-57.
136. Xu Y, Liu BR, Lee H-J, et al. Nona-arginine facilitates delivery of quantum dots into cells via multiple pathways. J Biomed Biotechnol 2010; 2010: 1-11.
137. Banoczi Z, Gorka-Kereskenyi A, Remenyi J, et al. Synthesis and in vitro antitumor effect of vinblastine derivative-oligoarginine conjugates. Bioconjug Chem 2010; 21: 1948-55.
138. Sakuma S, Suita M, Masaoka Y, et al. Oligoarginine-linked polymers as a new class of penetration enhancers. J Control Release 2010; 148: 187-96.
139. Morishita M, Kamei N, Ehara J, Isowa K, Takayama K. A novel approach using functional peptides for efficient intestinal absorption of insulin. J Control Release 2007; 118: 177-84.
140. Crombez L, Charnet A, Morris MC, Aldrian-Herrada G, Heitz F, Divita G. A non-covalent peptide-based strategy for siRNA delivery. Biochem Soc Trans 2007; 35: 44-6.
141. Veldhoen S, Laufer SD, Trampe A, Restle T. Cellular delivery of small interfering RNA by a non-covalently attached cellpenetrating peptide: quantitative analysis of uptake and biological effect. Nucleic Acids Res 2006; 34: 6561-73.
142. Lundberg P, El-Andaloussi S, Sütlü T, Johansson H, Langel Ü. Delivery of short interfering RNA using endosomolytic cellpenetrating peptides. FASEB J 2007; 21: 2664-71.
143. Simeoni F, Morris MC, Heitz F, Divita G. Insight into the mechanism of the peptide-based gene delivery system MPG: implications for delivery of siRNA into mammalian cells. Nucleic Acids Res 2003; 31: 2717-24.
144. Crombez L, Morris MC, Heitz F, Divita G. A non-covalent peptide-based strategy for ex vivo and in vivo oligonucleotide delivery. In: Goodchild J, editor. Therapeutic Oligonucleotides2011. p. 59-73.
145. Deshayes S, Morris MC, Heitz F, Divita G. Delivery of proteins and nucleic acids using a non-covalent peptide-based strategy. Adv Drug Deliv Rev 2008; 60: 537-47.
146. Deshayes S, Konate K, Aldrian G, Crombez L, Heitz F, Divita G. Structural polymorphism of non-covalent peptide-based delivery systems: Highway to cellular uptake. Biochim Biophys Acta 2010; 1798: 2304-14.
147. Morris MC, Chaloin L, Méry J, Heitz F, Divita G. A novel potent strategy for gene delivery using a single peptide vector as a carrier. Nucleic Acids Res 1999; 27: 3510-7.
148. Kilk K, El-Andaloussi S, Järver P, et al. Evaluation of transportan 10 in PEI mediated plasmid delivery assay. J Control Release 2005; 103: 511-23.
149. El-Andaloussi S, Johansson H, Magnusdottir A, Järver P, Lundberg P, Langel Ü. TP10, a delivery vector for decoy oligonucleotides targeting the Myc protein. J Control Release 2005; 110: 189-201.
150. Mäe M, Myrberg H, Andaloussi SE, Langel Ü. Design of a tumor homing cell-penetrating peptide for drug delivery. Int J Pept Res Ther 2009; 15: 11-5.
151. Ötenson C-G, Sandberg-Nordqvist A-C, Chen J, et al. Overexpression of protein-tyrosine phosphatase PTP sigma is linked to impaired glucose-induced insulin secretion in hereditary diabetic Goto-Kakizaki rats. Biochem Biophys Res Commun 2002; 291: 945-50.
152. Nishikawa M, Otsuki T, Ota A, et al. Induction of tumor-specific immune response by gene transfer of Hsp70-cell-penetrating peptide fusion protein to tumors in mice. Mol Ther 2010; 18: 421-8.
153. Lemken ML, Wolf C, Wybranietz WA, et al. Evidence for intercellular trafficking of VP22 in living cells. Mol Ther 2007; 15: 310-9.
154. Phelan A, Elliott G, O'Hare P. Intercellular delivery of functional p53 by the herpesvirus protein VP22. Nat Biotechnol 1998; 16: 440-3.
155. Cashman SM, Sadowski SL, Morris DJ, Frederick J, Kumar-Singh R. Intercellular trafficking of adenovirus-delivered HSV VP22 from the retinal pigment epithelium to the photoreceptors-Implications for gene therapy. Mol Ther 2002; 6: 813-23.
156. Wybranietz WA, Prinz F, Spiegel M, et al. Quantification of VP22-GFP spread by direct fluorescence in 15 commonly used cell lines. J Gene Med 1999; 1: 265-74.
157. Zender L, Kuhnel F, Kock R, Manns M, Kubicka S. VP22-mediated intercellular transport of p53 in hepatoma cells in vitro and in vivo. Cancer Gene Ther 2002; 9: 489-96.
158. Dilber MS, Phelan A, Aints A, et al. Intercellular delivery of thymidine kinase prodrug activating enzyme by the herpes simplex virus protein, VP22. Gene Ther 1999; 6: 12-21.
159. Zavaglia D, Favrot MC, Eymin B, Tenaud C, Coll JL. Intercellular trafficking and enhanced in vivo antitumour activity of a nonvirally delivered P27-VP22 fusion protein. Gene Ther 2003; 10: 314-25.
160. Wybranietz WA, Gross CD, Phelan A, et al. Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther 2001; 8: 1654-64.
161. Cheng CJ, Saltzman WM. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cellpenetrating peptides. Biomaterials 2011; 32: 6194-203.
162. Huang GQ, Wang JN, Tang JM, et al. The combined transduction of copper, zinc-superoxide dismutase and catalase mediated by cell-penetrating peptide, PEP-1, to protect myocardium from ischemia-reperfusion injury. J Transl Med 2011; 9: 73.
163. Kurzawa L, Pellerano M, Morris MC. PEP and CADY-mediated delivery of fluorescent peptides and proteins into living cells. Biochim Biophys Acta 2010; 1798: 2274-85.
164. Muñoz-Morris MA, Heitz F, Divita G, Morris MC. The peptide carrier Pep-1 forms biologically efficient nanoparticle complexes. Biochem Biophys Res Commun 2007; 355: 877-82.
165. Gros E, Deshayes S, Morris MC, et al. A non-covalent peptidebased strategy for protein and peptide nucleic acid transduction. Biochim Biophys Acta 2006; 1758: 384-93.
166. Chang J-C, Hsu S-h, Su H-L. The regulation of the gap junction of human mesenchymal stem cells through the internalization of quantum dots. Biomaterials 2009; 30: 1937-46.
167. Konate K, Crombez L, Deshayes S, et al. Insight into the cellular uptake mechanism of a secondary amphipathic cell-penetrating peptide for siRNA delivery. Biochemistry 2010; 49: 3393-402.
168. 4peptide allows efficient splicing correction in the absence of endosomolytic agents. J Control Release 2006; 116: 304-13.
169. 6-Penetratin delivery peptide. Nucleic Acids Res 2007; 35: 4495-502.
170. Yin H, Moulton HM, Seow Y, et al. Cell-penetrating peptideconjugated antisense oligonucleotides restore systemic muscle and cardiac dystrophin expression and function. Hum Mol Genet 2008; 17: 3909-18.
171. Ivanova GD, Arzumanov A, Abes R, et al. Improved cellpenetrating peptide-PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle. Nucleic Acids Res 2008; 36: 6418-28.
172. Berry C. Intracellular delivery of nanoparticles via the HIV-1 tat peptide. Nanomedicine 2008; 3: 357-65.
173. Gupta B, Levchenko TS, Torchilin VP. Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides. Adv Drug Deliv Rev 2005; 57: 637-51.
174. Elbayoumi TA, Pabba S, Roby A, Torchilin VP. Antinucleosome antibody-modified liposomes and lipid-core micelles for tumortargeted delivery of therapeutic and diagnostic agents. J Liposome Res 2007; 17: 1-14.
175. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebocontrolled, dose-escalation, proof-of-concept study. Lancet Neurol 2009; 8: 918-28.
176. Hassane SF, Saleh AF, Abes R, Gait M, Lebleu B. Cell penetrating peptides: overview and applications to the delivery of oligonucleotides Cell Mol Life Sci 2010; 67: 715-26.
177. Fletcher S, Honeyman K, Fall AM, et al. Morpholino oligomermediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 2007; 15: 1587-92.
178. Chen L, Harrison SD. Cell-penetrating peptides in drug development: enabling intracellular targets. Biochem Soc Trans 2007; 35: 821-5.
179. Foerg C, Merkle HP. On the biomedical promise of cell penetrating peptides: Limits versus prospects. J Pharm Sci 2008; 97: 144-62.
180. Duchardt F, Fotin-Mleczek M, Schwarz H, Fischer R, Brock R. A comprehensive model for the cellular uptake of cationic cellpenetrating peptides. Traffic 2007; 8: 848-66.
181. Lundin P, Johansson H, Guterstam P, et al. Distinct uptake routes of cell-penetrating peptide conjugates. Bioconjug Chem 2008; 19: 2535-42.
182. Hansen M, Eriste E, Langel Ü. The internalization mechanisms and bioactivity of the cell-penetrating peptides. Peptides as Drugs: Wiley-VCH Verlag GmbH & Co. KGaA; 2009. p. 125-43.
183. Madani F, Lindberg S, Langel Ü, Futaki S, Gräslund A. Mechanisms of cellular uptake of cell-penetrating peptides. J Biophys 2011; 2011.
184. Herce HD, Garcia AE. Cell penetrating peptides: how do they do it? J Biol Phys 2007; 33: 345-56.
185. Fittipaldi A, Ferrari A, Zoppé M, et al. Cell membrane lipid rafts mediate caveolar endocytosis of HIV-1 Tat fusion proteins. J Biol Chem 2003; 278: 34141-9.
186. Ferrari A, Pellegrini V, Arcangeli C, Fittipaldi A, Giacca M, Beltram F. Caveolae-mediated internalization of extracellular HIV-1 tat fusion proteins visualized in real time. Mol Ther 2003; 8: 284-94.
187. Nakase I, Tadokoro A, Kawabata N, et al. Interaction of argininerich peptides with membrane-associated proteoglycans is crucial for induction of actin organization and macropinocytosis. Biochemistry 2006; 46: 492-501.
188. Suzuki T, Futaki S, Niwa M, Tanaka S, Ueda K, Sugiura Y. Possible existence of common internalization mechanisms among arginine-rich peptides. J Biol Chem 2002; 277: 2437-43.
189. Silhol M, Tyagi M, Giacca M, Lebleu B, Vivès E. Different mechanisms for cellular internalization of the HIV-1 Tat-derived cell penetrating peptide and recombinant proteinsfused to Tat. Eur J Biochem 2002; 269: 494-501.
190. Fretz MM, Penning NA, AL-Taei S, et al. Temperature-, concentration-and cholesterol-dependent translocation of L-and D-octa-arginine across the plasma and nuclear membrane of CD34+ leukaemia cells. Biochem J 2007; 403: 335-42.
191. Tünnemann G, Martin RM, Haupt S, Patsch C, Edenhofer F, Cardoso MC. Cargo-dependent mode of uptake and bioavailability of TAT-containing proteins and peptides in living cells. FASEB J 2006; 20: 1775-84.
192. Veach RA, Liu D, Yao S, et al. Receptor/transporter-independent targeting of functional peptides across the plasma membrane. J Biol Chem 2004; 279: 11425-31.
193. Rothe R, Liguori L, Villegas-Mendez A, et al. Characterization of the Cell-penetrating Properties of the Epstein-Barr Virus ZEBRA trans-Activator. J Biol Chem 2010; 285: 20224-33.
194. Patel L, Zaro J, Shen W-C. Cell-penetrating-peptides: Intracellular pathways and pharmaceutical perspectives. Pharm Res 2007; 24: 1977-92.
195. El-Sayed A, Futaki S, Harashima H. Delivery of macromolecules using arginine-rich cell-penetrating peptides: Ways to overcome endosomal entrapment. AAPS J 2009; 11: 13-22.
196. Räägel H, Säälik P, Pooga M. Peptide-mediated protein delivery-Which pathways are penetrable? Biochim Biophys Acta 2010; 1798: 2240-8.
197. Conner SD, Schmid SL. Regulated portals of entry into the cell. Nature 2003; 422: 37-44.
198. Vercauteren D, Vandenbroucke RE, Jones AT, et al. The use of inhibitors to study endocytic pathways of gene carriers: optimization and pitfalls. Mol Ther 2010; 18: 561-9.
199. Doherty GJ, McMahon HT. Mechanisms of Endocytosis. Annu Rev Biochem 2009; 78: 857-902.
200. Lim JP, Gleeson PA. Macropinocytosis: an endocytic pathway for internalising large gulps. Immunol Cell Biol 2011; 89: 836-43.
201. Jones AT. Macropinocytosis: searching for an endocytic identity and role in the uptake of cell penetrating peptides. J Cell Mol Med 2007; 11: 670-84.
202. Nakase I, Niwa M, Takeuchi T, et al. Cellular uptake of argininerich peptides: roles for macropinocytosis and actin rearrangement. Mol Ther 2004; 10: 1011-22.
203. Chugh A, Eudes F. Study of uptake of cell penetrating peptides and their cargoes in permeabilized wheat immature embryos. FEBS J 2008; 275: 2403-14.
204. Pujals S, Fernandez-Carneado J, Kogan MJ, Martinez J, Cavelier F, Giralt E. Replacement of a proline with silaproline causes a 20-fold increase in the cellular uptake of a pro-rich peptide. J Am Chem Soc 2006; 128: 8479-83.
205. Mousavi S, Malerød L, Berg T, Kjeken R. Clathrin-dependent endocytosis. Biochem J 2004; 377: 1-16.
206. McMahon HT, Boucrot E. Molecular mechanism and physiological functions of clathrin-mediated endocytosis. Nat Rev Mol Cell Biol 2011; 12: 517-33.
207. Mercer J, Schelhaas M, Helenius A. Virus entry by endocytosis. Annu Rev Biochem 2010; 79: 803-33.
208. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 2007; 8: 603-12.
209. Smart EJ, Graf GA, McNiven MA, et al. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 1999; 19: 7289-304.
210. Le PU, Nabi IR. Distinct caveolae-mediated endocytic pathways target the Golgi apparatus and the endoplasmic reticulum. J Cell Sci 2003; 116: 1059-71.
211. Peters PJ, Mironov A, Peretz D, et al. Trafficking of prion proteins through a caveolae-mediated endosomal pathway. J Cell Biol 2003; 162: 703-17.
212. Martín I, Dohmen C, Mas-Moruno C, et al. Solid-phase-assisted synthesis of targeting peptide-PEG-oligo(ethane amino)amides for receptor-mediated gene delivery. Org Biomol Chem 2012; 10: 3258-68.
213. Hanrahan O, Harris J, Egan C. Advanced microscopy: laser scanning confocal microscopy. Methods Mol Biol 2011; 784: 169-80.
214. Harding C, Heuser J, Stahl P. Receptor-mediated endocytosis of transferrin and recycling of the transferrin receptor in rat reticulocytes. J Cell Biol 1983; 97: 329-39.
215. Wadia JS, Stan RV, Dowdy SF. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 2004; 10: 310-5.
216. Denk W, Strickler J, Webb W. Two-photon laser scanning fluorescence microscopy. Science 1990; 248: 73-6.
217. Clapp AR, Pons T, Medintz IL, et al. Two-photon excitation of quantum-dot-based fluorescence resonance energy transfer and its applications. Adv Mater 2007; 19: 1921-6.
218. Weill CO, Biri S, Adib A, Erbacher P. A practical approach for intracellular protein delivery. Cytotechnology 2008; 56: 41-8.
219. Loike JD, Silverstein SC. A fluorescence quenching technique using trypan blue to differentiate between attached and ingested glutaraldehyde-fixed red blood cells in phagocytosing murine macrophages. J Immunol Methods 1983; 57: 373-9.
220. Zaro JL, Rajapaksa TE, Okamoto CT, Shen W-C. Membrane transduction of oligoarginine in HeLa cells is not mediated by macropinocytosis. Mol Pharm 2006; 3: 181-6.
221. Ganguly S, Chaubey B, Tripathi S, et al. Pharmacokinetic analysis of polyamide nucleic-acid-cell penetrating peptide conjugates targeted against HIV-1 transactivation response element. Oligonucleotides 2008; 18: 277-86.
222. Aussedat B, Sagan S, Chassaing G, Bolbach G, Burlina F. Quantification of the efficiency of cargo delivery by peptidic and pseudo-peptidic Trojan carriers using MALDI-TOF mass spectrometry. Biochim Biophys Acta 2006; 1758: 375-83.
223. Aubry S, Aussedat B, Delaroche D, et al. MALDI-TOF mass spectrometry: A powerful tool to study the internalization of cellpenetrating peptides. Biochim Biophys Acta 2010; 1798: 2182-9.
224. Burlina F, Sagan S, Bolbach G, Chassaing G. A direct approach to quantification of the cellular uptake of cell-penetrating peptides using MALDI-TOF mass spectrometry. Nat Protocols 2006; 1: 200-5.
225. Kaczmarczyk SJ, Green JE. A single vector containing modified cre recombinase and LOX recombination sequences for inducible tissue-specific amplification of gene expression. Nucleic Acids Res 2001; 29: e56.
226. Dominski Z, Kole R. Restoration of correct splicing in thalassemic pre-mRNA by antisense oligonucleotides. Proc Natl Acad Sci USA 1993; 90: 8673-7.
227. Kang S-H, Cho M-J, Kole R. Up-regulation of luciferase gene expression with antisense oligonucleotides: implications and applications in functional assay development. Biochemistry 1998; 37: 6235-9.
228. Egholm M, Buchardt O, Nielsen PE, Berg RH. Peptide nucleic acids (PNA). Oligonucleotide analogs with an achiral peptide backbone. J Am Chem Soc 1992; 114: 1895-7.
229. Moulton HM, Wu B, Jearawiriyapaisarn N, Sazani P, Lu QL, Kole R. Peptide-morpholino conjugate: a promising therapeutic for Duchenne Muscular Dystrophy. Ann N Y Acad Sci 2009; 1175: 55-60.
230. Moulton HM, Nelson MH, Hatlevig SA, Reddy MT, Iversen PL. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides. Bioconjug Chem 2004; 15: 290-9.
231. Zaro JL, Shen W-C. Evidence that membrane transduction of oligoarginine does not require vesicle formation. Exp Cell Res 2005; 307: 164-73.
232. De Duve C, De Barsy T, Poole B, Trouet A, Tulkens P, Van Hoof Fo. Lysosomotropic agents. Biochem Pharmacol 1974; 23: 2495-531.
233. Bowman EJ, Siebers A, Altendorf K. Bafilomycins: a class of inhibitors of membrane ATPases from microorganisms, animal cells, and plant cells. Proc Natl Acad Sci USA 1988; 85: 7972-6.
234. Dennison SR, Baker RD, Nicholl ID, Phoenix DA. Interactions of cell penetrating peptide Tat with model membranes: A biophysical study. Biochem Biophys Res Commun 2007; 363: 178-82.
235. Ziegler A. Thermodynamic studies and binding mechanisms of cell-penetrating peptides with lipids and glycosaminoglycans. Adv Drug Deliv Rev 2008; 60: 580-97.
236. Thorén PEG, Persson D, Karlsson M, Nordén B. The Antennapedia peptide penetratin translocates across lipid bilayers-the first direct observation. FEBS Lett 2000; 482: 265-8.
237. Terrone D, Sang SLW, Roudaia L, Silvius JR. Penetratin and related cell-penetrating cationic peptides can translocate across lipid bilayers in the presence of a transbilayer potential. Biochemistry 2003; 42: 13787-99.
238. Brooks NA, Pouniotis DS, Tang C-K, Apostolopoulos V, Pietersz GA. Cell-penetrating peptides: Application in vaccine delivery. Biochim Biophys Acta 2010; 1805: 25-34.
239. Simons K, Toomre D. Lipid rafts and signal transduction. Nat Rev Mol Cell Biol 2000; 1: 31-9.
240. Jiao C-Y, Delaroche D, Burlina F, Alves ID, Chassaing G, Sagan S. Translocation and endocytosis for cell-penetrating peptide internalization. J Biol Chem 2009; 284: 33957-65.
241. Puckett CA, Barton JK. Fluorescein redirects a rutheniumoctaarginine conjugate to the nucleus. J Am Chem Soc 2009; 131: 8738-9.
242. Rittner K, Benavente A, Bompard-Sorlet A, et al. New basic membrane-destabilizing peptides for plasmid-based gene delivery in vitro and in vivo. Mol Ther 2002; 5: 104-14.
243. Deshayes S, Morris MC, Divita G, Heitz F. Cell-penetrating peptides: tools for intracellular delivery of therapeutics. Cell Mol Life Sci 2005; 62: 1839-49.
244. Gerbal-Chaloin S, Gondeau C, Aldrian-Herrada G, Heitz F, Gauthier-Rouvière C, Divita G. First step of the cell-penetrating peptide mechanism involves Rac1 GTPase-dependent actinnetwork remodelling. Biol Cell 2007; 99: 223-38.
245. Aoshiba K, Yokohori N, Nagai A. Alveolar wall apoptosis causes lung destruction and emphysematous changes. Am J Respir Cell Mol Biol 2003; 28: 555-62.
246. Maron MB, Folkesson HG, Stader SM, Walro JM. PKA delivery to the distal lung air spaces increases alveolar liquid clearance after isoproterenol-induced alveolar epithelial PKA desensitization. Am J Physiol Lung Cell Mol Physiol 2005; 289: 349-54.
247. Sik Eum W, Won Kim D, Koo Hwang I, et al. In vivo protein transduction: biologically active intact pep-1-superoxide dismutase fusion protein efficiently protects against ischemic insult. Free Radic Biol Med 2004; 37: 1656-69.
248. Morris MC, Chaloin L, Choob M, Archdeacon J, Heitz F, Divita G. Combination of a new generation of PNAs with a peptide-based carrier enables efficient targeting of cell cycle progression. Gene Ther 2004; 11: 757-64.
249. Kosuge M, Takeuchi T, Nakase I, Jones AT, Futaki S. Cellular internalization and distribution of arginine-rich peptides as a function of extracellular peptide concentration, serum, and plasma membrane associated proteoglycans. Bioconjug Chem 2008; 19: 656-64.
250. Manceur A, Wu A, Audet J. Flow cytometric screening of cellpenetrating peptides for their uptake into embryonic and adult stem cells. Anal Biochem 2007; 364: 51-9.
251. Maiolo JR, Ferrer M, Ottinger EA. Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim Biophys Acta 2005; 1712: 161-72.
252. Fischer R, Köhler K, Fotin-Mleczek M, Brock R. A stepwise dissection of the intracellular fate of cationic cell-penetrating peptides. Journal of Biological Chemistry 2004; 279: 12625-35.
253. Mueller J, Kretzschmar I, Volkmer R, Boisguerin P. Comparison of cellular uptake using 22 CPPs in 4 different cell lines. Bioconjug Chem 2008; 19: 2363-74.
254. Szeto HH, Schiller PW, Zhao K, Luo G. Fluorescent dyes alter intracellular targeting and function of cell-penetrating tetrapeptides. FASEB J 2005; 19: 118-20.
255. El-Andaloussi S, Järver P, Johansson HJ, Langel Ü. Cargodependent cytotoxicity and delivery efficacy of cell-penetrating peptides: a comparative study. Biochem J 2007; 407: 285-92.
256. Sakai N, Takeuchi T, Futaki S, Matile S. Direct observation of anion-mediated translocation of fluorescent oligoarginine carriers into and across bulk liquid and anionic bilayer membranes. ChemBioChem 2005; 6: 114-22.
257. Sakai N, Matile S. Anion-mediated transfer of polyarginine across liquid and bilayer membranes. J Am Chem Soc 2003; 125: 14348-56.
258. Rothbard JB, Jessop TC, Lewis RS, Murray BA, Wender PA. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J Am Chem Soc 2004; 126: 9506-7.
259. Rothbard JB, Jessop TC, Wender PA. Adaptive translocation: the role of hydrogen bonding and membrane potential in the uptake of guanidinium-rich transporters into cells. Adv Drug Deliv Rev 2005; 57: 495-504.
260. Som A, Xu Y, Scott RW, Tew GN. Anion mediated activation of guanidine rich small molecules. Org Biomol Chem 2012; 10: 40-2.
261. Inomata K, Ohno A, Tochio H, et al. High-resolution multidimensional NMR spectroscopy of proteins in human cells. Nature 2009; 458: 106-9.
262. Perret F, Nishihara M, Takeuchi T, et al. Anionic fullerenes, calixarenes, coronenes, and pyrenes as activators of oligo/polyarginines in model membranes and live cells. J Am Chem Soc 2005; 127: 1114-5.
263. Sakai N, Futaki S, Matile S. Anion hopping of (and on) functional oligoarginines: from chloroform to cells. Soft Matter 2006; 2: 636-41.
264. Guterstam P, Madani F, Hirose H, et al. Elucidating cellpenetrating peptide mechanisms of action for membrane interaction, cellular uptake, and translocation utilizing the hydrophobic counter-anion pyrenebutyrate. Biochim Biophys Acta 2009; 1788: 2509-17.
265. Jablonski AE, Kawakami T, Ting AY, Payne CK. Pyrenebutyrate leads to cellular binding, not intracellular delivery, of polyarginine quantum dots. J Phys Chem Lett 2010; 1: 1312-5.
266. Susumu K, Uyeda HT, Medintz IL, Pons T, Delehanty JB, Mattoussi H. Enhancing the stability and biological functionalities of quantum dots via compact multifunctional ligands. J Am Chem Soc 2007; 129: 13987-96.
267. Zhou M, Ghosh I. Quantum dots and peptides: A bright future together. Pept Sci 2007; 88: 325-39.
268. Voura EB, Jaiswal JK, Mattoussi H, Simon SM. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med 2004; 10: 993-8.
269. Medintz IL, Uyeda HT, Goldman ER, Mattoussi H. Quantum dot bioconjugates for imaging, labelling and sensing. Nat Mater 2005; 4: 435-46.
270. Delehanty JB, Medintz IL, Pons T, Brunel FM, Dawson PE, Mattoussi H. Self-assembled quantum dot-peptide bioconjugates for selective intracellular delivery. Bioconjug Chem 2006; 17: 920-7.
271. Midoux P, Monsigny M. Efficient gene transfer by histidylated polylysine/pDNA complexes. Bioconjug Chem 1999; 10: 406-11.
272. Delehanty JB, Bradburne CE, Boeneman K, et al. Delivering quantum dot-peptide bioconjugates to the cellular cytosol: Escaping from the endolysosomal system. Integr Biol 2010; 2: 265-77.
273. Lagerholm BC, Wang M, Ernst LA, et al. Multicolor coding of cells with cationic peptide coated quantum dots. Nano Lett 2004; 4: 2019-22.
274. Silver J, Ou W. Photoactivation of quantum dot fluorescence following endocytosis. Nano Lett 2005; 5: 1445-9.
275. Falanga A, Vitiello MT, Cantisani M, et al. A peptide derived from herpes simplex virus type 1 glycoprotein H: Membrane translocation and applications to the delivery of quantum dots. Nanomedicine 2011; 7: 925-34.
276. Yukawa H, Kagami Y, Watanabe M, et al. Quantum dots labeling using octa-arginine peptides for imaging of adipose tissue-derived stem cells. Biomaterials 2010; 31: 4094-103.
277. Rozenzhak SM, Kadakia MP, Caserta TM, Westbrook TR, Stone MO, Naik RR. Cellular internalization and targeting of semiconductor quantum dots. Chem Commun 2005: 2217-9.
278. Lieleg O, López-García M, Semmrich C, Auernheimer J, Kessler H, Bausch AR. Specific integrin labeling in living cells using functionalized nanocrystals. Small 2007; 3: 1560-5.
279. Smith BR, Cheng Z, De A, Koh AL, Sinclair R, Gambhir SS. Realtime intravital imaging of RGD-quantum dot binding to luminal endothelium in mouse tumor neovasculature. Nano Lett 2008; 8: 2599-606.
280. Sueblinvong V, Suratt BT, Weiss DJ. Novel therapies for the treatment of cystic fibrosis: New developments in gene and stem cell therapy. Clin Chest Med 2007; 28: 361-79.
281. Kundu PP, Sharma V. Synthetic polymeric vectors in gene therapy. Curr Opin Solid State Mater Sci 2008; 12: 89-102.
282. Cross D, Burmester JK. Gene therapy for cancer treatment: past, present and future. Clin Med Res 2006; 4: 218-27.
283. Feldman AL, Libutti SK. Progress in antiangiogenic gene therapy of cancer. Cancer 2000; 89: 1181-94.
284. Gómez-Navarro J, Curiel DT, Douglas JT. Gene therapy for cancer. Eur J Cancer 1999; 35: 867-85.
285. Folkman J. Antiangiogenic gene therapy. Proc Natl Acad Sci USA 1998; 95: 9064-6.
286. Dunnett SB, Björklund A. Prospects for new restorative and neuroprotective treatments in Parkinson's disease. Nature 1999; 399: A32-A9.
287. Liu Y, Huang R, Jiang C. Non-viral gene delivery and therapeutics targeting to brain. Curr Nanosci 2011; 7: 55-70.
288. Kaye EM, Sena-Esteves M. Gene therapy for the central nervous system in the lysosomal storage disorders. Neurol Clin 2002; 20: 879-901.
289. Ponder KP. Systemic gene therapy for cardiovascular disease. Trends Cardiovasc Med 1999; 9: 158-62.
290. Nabel EG. Gene Transfer Approaches for Cardiovascular Disease. In: R. K, Chien MD, editors. Molecular Basis of Cardiovascular Disease (Second Edition). Philadelphia: W.B. Saunders; 2004. p. 195-216.
291. Rapti K, Chaanine AH, Hajjar RJ. Targeted gene therapy for the treatment of heart failure. Can J Cardiol 2011; 27: 265-83.
292. Poluri A, van Maanen M, Sutton RE. Genetic therapy for HIV/AIDS. Expert Opin Biol Ther 2003; 3: 951-63.
293. Chadwick DR, Lever AM. Gene therapy for HIV infection. Expert Opin Ther Pat 1998; 8: 983-90.
294. Colella P, Cotugno G, Auricchio A. Ocular gene therapy: current progress and future prospects. Trends Mol Med 2009; 15: 23-31.
295. Sakamoto T, Ikeda Y, Yonemitsu Y. Gene targeting to the retina. Adv Drug Deliv Rev 2001; 52: 93-102.
296. Evans CH, Gouze E, Gouze JN, Robbins PD, Ghivizzani SC. Gene therapeutic approaches-transfer in vivo. Adv Drug Deliv Rev 2006; 58: 243-58.
297. Bonadio J, Goldstein SA, Levy RJ. Gene therapy for tissue repair and regeneration. Adv Drug Deliv Rev 1998; 33: 53-69.
298. Lo SL, Wang S. An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection. Biomaterials 2008; 29: 2408-14.
299. Yi WJ, Yang J, Li C, et al. Enhanced nuclear import and transfection efficiency of TAT peptide-based gene delivery systems modified by additional nuclear localization signals. Bioconjug Chem 2011; 23: 125-34.
300. Nakase I, Akita H, Kogure K, et al. Efficient intracellular delivery of nucleic acid pharmaceuticals using cell-penetrating peptides. Acc Chem Res 2011.
301. Moschos SA, Jones SW, Perry MM, et al. Lung delivery studies using siRNA conjugated to TAT(48-60) and penetratin reveal peptide induced reduction in gene expression and induction of innate immunity. Bioconjug Chem 2007; 18: 1450-9.
302. Moulton HM. Antisense morpholino oligomers and theirs peptide conjugates. In: Chemistry ERSo, editor. Therapeutic Oligonucleotide. Cambridge2008. p. 43-79.
303. Morris MC, Gros E, Aldrian-Herrada G, et al. A non-covalent peptide-based carrier for in vivo delivery of DNA mimics. Nucleic Acids Res 2007; 35: e49.
304. Moulton HM, Fletcher S, Neuman BW, et al. Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans 2007; 035: 826-8.
305. Androic I, Kramer A, Yan R, Rodel F, Gatje R, Kaufmann M, et al. Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer 2008; 8: 391.
306. Crombez L, Morris MC, Dufort S, et al. Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res 2009; 37: 4559-69.